These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26071758)

  • 21. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
    ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
    Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 23. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
    Teft WA; Mansell SE; Kim RB
    Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
    Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
    Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
    Henderson SL; Teft WA; Kim RB
    BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
    Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
    Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pharmacokinetic-Pharmacodynamic Model of Tamoxifen and Endoxifen to Predict Their Distribution and Effects on Inhibition of Tumor Growth.
    Yuan S; Sun Q; Chen Y; Liao J
    Drug Metab Lett; 2017; 11(2):93-101. PubMed ID: 28814243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
    Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
    Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
    Jansen LE; Teft WA; Rose RV; Lizotte DJ; Kim RB
    Breast Cancer Res Treat; 2018 Oct; 171(3):701-708. PubMed ID: 29980881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
    Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Sideras K; Ingle JN; Ames MM; Loprinzi CL; Mrazek DP; Black JL; Weinshilboum RM; Hawse JR; Spelsberg TC; Goetz MP
    J Clin Oncol; 2010 Jun; 28(16):2768-76. PubMed ID: 20439629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in the research of pharmacogenomics of tamoxifen].
    Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
    Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells.
    Ribeiro MP; Silva FS; Paixão J; Santos AE; Custódio JB
    Eur J Pharmacol; 2013 Sep; 715(1-3):354-62. PubMed ID: 23712006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
    Chao TC; Pan WC; Tsai YF; Chou YC; Liu YR; Wang SF; Chen YJ; Souček P; Ueng YF
    Toxicol Appl Pharmacol; 2019 Sep; 378():114619. PubMed ID: 31195002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.